Search

everythinglearnresearchcommunity

for

Search:↓

Patients with melanoma who saw dermatologists and were from higher-income areas were more likely to have follow-up visits, which was linked to lower mortality.

WYE-130600 may cause skin thickening and irritation.

Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.

Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.

BRAF inhibitors for melanoma often cause skin side effects, but they can be managed with proper care.

New cancer drugs often cause skin and nail problems.

Vemurafenib therapy can cause hair loss, but clobetasol propionate foam can help regrow hair.

The combination of encorafenib and binimetinib caused few skin issues.

Doctors should actively prevent and treat skin side effects in cancer patients to keep them on the best medication and reduce discomfort.

Vemurafenib can cause scalp issues but can be managed without changing the dose.

New cancer treatments are less harmful to hair but can still cause hair loss, color, shape, and growth changes.

Blocking RANK signaling might help treat metastatic melanoma, but more research is needed.

Cancer treatments can cause hair loss, but it is often reversible and can be managed with scalp cooling and support.

Thymic LCH may be underdiagnosed, so thymic ultrasound should be considered in infants with cutaneous LCH.

The document concludes that understanding nail anatomy is key for diagnosing nail diseases, early signs of nail melanoma may allow for less aggressive treatment, and specific genetic mutations are important in thyroid cancer prognosis and treatment.

Targeted cancer drugs can cause skin reactions, so dermatologists must manage these effects.

Vemurafenib causes skin side effects similar to RASopathies, requiring regular skin checks and UVA protection.

RET mutation is important in familial medullary thyroid carcinoma, and BRAF mutation in papillary thyroid carcinoma is linked to more aggressive cancer and higher death rates.

Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.

The drug showed promise in treating renal cell carcinoma with manageable side effects.

Sorafenib after liver surgery may increase survival for some liver cancer patients.

Non-scarring hair loss can be diagnosed with two 4mm punch biopsies, one cut vertically and the other transversely.

Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.

Afatinib often causes skin problems that need proactive management.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

A man treated with gefitinib for lung cancer grew new hair on his bald scalp.

Imatinib can repigment grey hair, while SU11428 can cause temporary hair depigmentation.

New therapies for Birt–Hogg–Dubé syndrome are being developed based on understanding the FLCN gene's role.

A bull with a gene mutation was asymptomatic, synthetic retinoids cause hair loss, and new therapeutic targets were identified for skin diseases.